Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 35.

Journal Article

Ackermann, S., Cartolano, M., Hero, B., Roderwieser, A., Bartenhagen, C., Rosswog, C., Hertwig, F., Simon, T., Eggert, A., Speleman, F., Buettner, R., O'Sullivan, R., Thomas, R., Berthold, F., Vandesompele, J., Schramm, A., Westermann, F., Schulte, J., Peifer, M. and Fischer, M. (2018). A Mechanistic Classification of Clinical Phenotypes in Neuroblastoma. Pediatr. Blood Cancer, 65. S. S87 - 2. HOBOKEN: WILEY. ISSN 1545-5017

Ackermann, S., Cartolano, M., Hero, B., Roderwieser, A., Bartenhagen, C., Rosswog, C., Hertwig, F., Simon, T., Eggert, A., Speleman, F., Buettner, R., O'sullivan, R., Thomas, R., Berthold, F., Vandesompele, J., Schramm, A., Westermann, F., Schulte, J., Peifer, M. and Fischer, M. (2018). A Mechanistic Classification of Clinical Phenotypes in Neuroblastoma. Pediatr. Blood Cancer, 65. S. S234 - 1. HOBOKEN: WILEY. ISSN 1545-5017

Arenz, D., Hero, B., Eichhorst, B. F., Langer, M., Pester, L., von Tresckow, J., Vehreschild, M. J. G. and Cornely, O. A. (2014). Estimating Site Costs Prior to Conducting Clinical Trials - a Study Site Budgeting Tool. Oncol. Res. Treat., 37. S. 32 - 33. BASEL: KARGER. ISSN 2296-5262

Berthold, F., Faldum, A., Ernst, A., Boos, J., Dilloo, D., Eggert, A., Fischer, M., Fruehwald, M., Henze, G., Klingebiel, T., Kratz, C., Kremens, B., Krug, B., Leuschner, I, Schmidt, M., Schmidt, R., Schumacher-Kuckelkorn, R., von Schweinitz, D., Schilling, F. H., Theissen, J., Volland, R., Hero, B. and Simon, T. (2020). Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR. Ann. Oncol., 31 (3). S. 422 - 430. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Berthold, F., Volland, R., Proleskovskaya, I., Mazanek, P., Belogurova, M., Hoemberg, M., Simon, T., Hero, B. and Sterba, J. (2015). METRONOMIC THERAPY AS LOW TOXIC AND EFFECTIVE TREATMENT FOR RECURRENCES OF HIGH RISK NEUROBLASTOMA. Pediatr. Blood Cancer, 62. S. S178 - 1. HOBOKEN: WILEY. ISSN 1545-5017

Cernaianu, G., Simon, T., Hero, B. and Duebbers, M. (2017). Lack of Renal Artery Inspection is Associated with Low Resectability at the Renal Hilus in Relapsed High-Risk Neuroblastoma. Pediatr. Blood Cancer, 64. S. S162 - 1. HOBOKEN: WILEY. ISSN 1545-5017

Deubzer, H., Fabian, J., Opitz, D., Althoff, K., Lodrini, M., Astrahantseff, K., Hero, B., Volland, R., Beckers, A., De Preter, K., Patil, N., Abba, M., Wuenchel, J., Thole, T., Hu, J., Schweitzer, L., Mechtersheimer, G., Carter, D., Cheung, B., Popanda, O., von Deimling, A., Henrich, K. O., Westermann, F., Schwab, M., Koster, J., Versteeg, R., Marshall, G., Speleman, F., Zoeller, M., Allgayer, H., Fischer, M., Berthold, F., Kulozik, A., Witt, O., Schulte, J. and Eggert, A. (2015). MYCN TRANSCRIPTIONALLY REPRESSES CD9 TO TRIGGER AN INVASION-METASTASIS CASCADE IN NEUROBLASTOMA. Pediatr. Blood Cancer, 62. S. S150 - 1. HOBOKEN: WILEY-BLACKWELL. ISSN 1545-5017

Dorneburg, C., Fischer, M., Barth, T. F. E., Mueller-Klieser, W., Hero, B., Gecht, J., Carter, D. R., de Preter, K., Speleman, F., Marshall, G. M., Christner, L., Debatin, K. M. and Beltinger, C. (2018). LDHA Predicts Poor Survival in Neuroblastoma and its Depletion Causes Aerobic Glycolysis-Independent Inhibition of Neuroblastoma Cells. Pediatr. Blood Cancer, 65. S. S238 - 1. HOBOKEN: WILEY. ISSN 1545-5017

Eggert, A., Schramm, A., Koester, J., Assenov, Y., Kristina, A., Engesser, A., Kahlert, Y., Theissen, J., Hero, B., Roels, F., Peifer, M., Astrahantseff, K., Depreter, K., Lode, H., Speleman, F., Schmezer, P., Westermann, F., Rahmann, S., Fischer, M. and Schulte, J. (2015). INTEGRATED GENOMIC ANALYSIS IDENTIFIES SPECIFIC ALTERATIONS AND ACTIVATION OF YAP IN RELAPSED NEUROBLASTOMA. Pediatr. Blood Cancer, 62. S. S145 - 1. HOBOKEN: WILEY-BLACKWELL. ISSN 1545-5017

Fischer, M., Oberthuer, A., Juraeva, D., Schmidt, R., Faldum, A., Berthold, F., Westermann, F., Brors, B., Simon, T. and Hero, B. (2014). REVISED RISK ESTIMATION AND TREATMENT STRATIFICATION OF LOW- AND INTERMEDIATE-RISK NEUROBLASTOMA PATIENTS BY INTEGRATING CLINICAL AND MOLECULAR PROGNOSTIC MARKERS. Pediatr. Blood Cancer, 61. S. S119 - 2. HOBOKEN: WILEY-BLACKWELL. ISSN 1545-5017

Hero, B., Simon, T., Lode, H., Eggert, A. and Berthold, F. (2017). Feasibility and Toxicity of Busulfan and Melphalan Conditioning Regimen in the Context of the German Induction Chemotherapy. Pediatr. Blood Cancer, 64. S. S34 - 2. HOBOKEN: WILEY. ISSN 1545-5017

Hero, B., Simon, T., Volland, R., Eggert, A., Fischer, M. and Berthold, F. (2015). BENIGN COURSE OF DISEASE IN LOCALIZED NEUROBLASTOMA SHOWING RELAPSE OR PROGRESSION. Pediatr. Blood Cancer, 62. S. S178 - 1. HOBOKEN: WILEY-BLACKWELL. ISSN 1545-5017

Hoyer-Kuhn, H., Franklin, J., Allo, G., Kron, M., Netzer, C., Eysel, P., Hero, B., Schoenau, E. and Semler, O. (2016). Safety and efficacy of denosumab in children with osteogenesis imperfecta - a first prospective trial. J. Musculoskelet. Neuronal Interact., 16 (1). S. 24 - 33. NAFPLION: JMNI. ISSN 1108-7161

Ikram, F., Ackermann, S., Roels, E., Volland, R., Hero, B., Hertwig, F., Kocak, H., Dreidax, D., Henrich, K. O., Berthold, F., Nuernberg, P., Westermann, F. and Fischer, M. (2014). Transcription factor activating protein 2 beta (TFAP2B) mediates neuronal differentiation in neuroblastoma. Eur. J. Cancer, 50. S. 130 - 132. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852

Krumbholz, M., Bradtke, J., Stachel, D., Peters, O., Hero, B., Holter, W., Slany, R. and Metzler, M. (2015). From initiation to eradication: the lifespan of an MLL-rearranged therapy-related paediatric AML. Bone Marrow Transplant., 50 (10). S. 1382 - 1385. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

London, W., Moroz, V., Hero, B., Park, J. R., Valteau-Couanet, D., Nakagawara, A., Berthold, F., Matthay, K. K., Schleiermacher, G. and Machin, D. (2014). A NEUROBLASTOMA RISK CLASSIFICATION MODEL FOR DEVELOPING COUNTRIES: A STUDY FROM THE INTERNATIONAL NEUROBLASTOMA (NB) RISK GROUP (INRG) DATABASE. Pediatr. Blood Cancer, 61. S. S119 - 1. HOBOKEN: WILEY-BLACKWELL. ISSN 1545-5017

Matser, Y., Verly, I., De Sain-Van der Velden, M., Wieczorek, A., Vicha, A., Ash, S., Pasqualini, C., Beck-Popovic, M., Schleiermacher, G., Canete, A., Owens, C., Ora, I., De Wilde, B., Cangemi, G., Garaventa, A., Grouzmann, E., Papadakis, V., Simon, T., Hero, B., Van Kuilenburg, A. and Tytgat, G. (2020). Optimising Urinary Catecholamine Diagnostics for Neuroblastoma Patients. Pediatr. Blood Cancer, 67. S. S278 - 1. HOBOKEN: WILEY. ISSN 1545-5017

Peifer, M., Hertwig, F., Roels, F., Dreidax, D., Gartlgruber, M., Menon, R., Hero, B., Schramm, A., Schulte, J. H., Herrmann, C., O'Sullivan, R. J., Westermann, F., Thomas, R. K. and Fischer, M. (2016). Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Oncol. Res. Treat., 39. S. 43 - 44. BASEL: KARGER. ISSN 2296-5262

Peifer, M., Roels, F., Hertwig, F., Menon, R., Kraemer, A., Buettner, R., Perner, S., Schramm, A., Schulte, J. H., Hero, B., O'Sullivan, R. J., Westermann, F., Thomas, R. K. and Fischer, M. (2015). TELOMERASE ACTIVATION BY RECURRENT GENOMIC REARRANGEMENTS IN HIGH-RISK NEUROBLASTOMA. Pediatr. Blood Cancer, 62. S. S149 - 2. HOBOKEN: WILEY-BLACKWELL. ISSN 1545-5017

Platschek, A-M., Simon, T., Hero, B. and Strueder, H. K. (2020). Relationship of Cancer-Related Fatigue and Physical Activity in Pediatric Oncology Depending on Age. Pediatr. Blood Cancer, 67. S. S324 - 2. HOBOKEN: WILEY. ISSN 1545-5017

Platschek, A. M., Abeln, V., Hero, B., Simon, T. and Strueder, H. K. (2017). Factors Affecting Fatigue in Pediatric Oncology Patients. Pediatr. Blood Cancer, 64. S. S478 - 2. HOBOKEN: WILEY. ISSN 1545-5017

Platschek, A. M., Kukutschka, C., Simon, T., Hero, B., Foitschik, T. and Strueder, H. K. (2018). Cancer-Related Fatigue: What Potential has Physical Activity? Pediatr. Blood Cancer, 65. S. S532 - 1. HOBOKEN: WILEY. ISSN 1545-5017

Platschek, A. M., Simon, T., Hero, B., Foitschik, T. and Strueder, H. K. (2018). Changes in Activity Behavior at the Beginning of Cancer Therapy. Pediatr. Blood Cancer, 65. S. S532 - 2. HOBOKEN: WILEY. ISSN 1545-5017

Rosswog, C., Bartenhagen, C., Engesser, A., Kahlert, Y., Hertwig, F., Roderwieser, A., Hero, B., Peifer, M., Thomas, R. and Fischer, M. (2018). Reconstructing the Evolution of Complex Genomic Amplification Patterns at Chromosome 12q in Neuroblastoma. Pediatr. Blood Cancer, 65. S. S277 - 2. HOBOKEN: WILEY. ISSN 1545-5017

Rosswog, C., Fassunke, J., Schoemig-Markiefka, B., Merkelbach-Bruse, S., Ackermann, S., Ortmann, M., Schulte, J., Westermann, F., Berthold, F., Simon, T., Hero, B. and Fischer, M. (2020). ALK Mutations in Primary and Relapsed Neuroblastoma in a GPOH Cohort. Pediatr. Blood Cancer, 67. S. S57 - 2. HOBOKEN: WILEY. ISSN 1545-5017

Rosswog, C., Schmidt, R., Oberthuer, A., Juraeva, D., Brors, B., Westermann, F., Berthold, F., Simon, T., Hero, B., Faldum, A. and Fischer, M. (2015). DEVELOPMENT OF A SCORING SYSTEM BASED ON A PROGNOSTIC INDEX FOR RISK ASSESSMENT OF PATIENTS WITH NEUROBLASTOMA. Pediatr. Blood Cancer, 62. S. S178 - 2. HOBOKEN: WILEY-BLACKWELL. ISSN 1545-5017

Schmidt, M. C., Hero, B., Decarolis, B., Eggert, A., Berthold, F., Drzezga, A. and Simon, T. (2017). I-131-mIBG therapy in high-risk neuroblastoma patients at end of induction chemotherapy. Eur. J. Nucl. Med. Mol. Imaging, 44. S. S772 - 1. NEW YORK: SPRINGER. ISSN 1619-7089

Schmidt, M. C., Hero, B., Decarolis, B., Eggert, A., Berthold, F., Drzezga, A. and Simon, T. (2016). I-131-meta-iodobenzylguanidine therapy improves survival in high-risk neuroblastoma patients with I-123-mIBG positive residual metastatic disease. Eur. J. Nucl. Med. Mol. Imaging, 43. S. S31 - 1. NEW YORK: SPRINGER. ISSN 1619-7089

Simon, T., Hero, B., Ruth, V., Angelika, E. and Frank, B. (2016). Improved Long-Term Survival after Myeloablative Chemotherapy with Autologous Stem Cell Transplantation in High-Risk Neuroblastoma Patients. Results of the NB97 Trial. Pediatr. Blood Cancer, 63. S. S39 - 1. HOBOKEN: WILEY-BLACKWELL. ISSN 1545-5017

Simon, T., Schmidt, M., Decarolis, B., Eggert, A., Berthold, F. and Hero, B. (2017). I-131-Meta-Iodobenzylguanidine (MIBG) Therapy Improves Survival in High-Risk Neuroblastoma Patients with MIBG Positive Residual Metastatic Disease. Pediatr. Blood Cancer, 64. S. S33 - 2. HOBOKEN: WILEY. ISSN 1545-5017

Stark, C., Herkenrath, P., Hollmann, H., Waltz, S., Becker, I., Hoebing, L., Semler, O., Hoyer-Kuhn, H., Duran, I., Hero, B., Hadders-Algra, M. and Schoenau, E. (2016). Early vibration assisted physiotherapy in toddlers with cerebral palsy - a randomized controlled pilot trial. J. Musculoskelet. Neuronal Interact., 16 (3). S. 183 - 193. NAFPLION: JMNI. ISSN 1108-7161

Van Zogchel, L., De Carolis, B., van Wezel, E., Stutterheim, J., Zappeij-Kannegieter, L., van Doornum, M., Schumacher-Kuckelkorn, R., Gecht, J., Simon, T., Caron, H., Fiocco, M., van der Schoot, E., Hero, B., Berthold, F. and Tytgat, G. (2018). Detection of Minimal Residual Disease (MRD) in High Risk Neuroblastoma Correlates with Outcome: Final Results of International GPOH-DCOG Prospective Validation Study. Pediatr. Blood Cancer, 65. S. S38 - 1. HOBOKEN: WILEY. ISSN 1545-5017

Volland, R., Simon, T., Berthold, F. and Hero, B. (2015). CONFIRMATION OF THE INRG SURVIVAL TREE ANALYSIS BY A DIFFERENTLY COMPOSED REPRESENTATIVE NATIONAL COHORT OF PATIENTS. Pediatr. Blood Cancer, 62. S. S226 - 1. HOBOKEN: WILEY-BLACKWELL. ISSN 1545-5017

Waack, K., Wulff, B., Roellecke, K., Schneider, D., Paulussen, M., Zuzak, T., Laengler, A., Niehues, T., Brauer, N., Feddersen, I., Kontny, U., Calaminus, G., Dilloo, D., Irnich, M., Prokop, A., Graf, N., Hero, B., Fischer, M., Simon, T. and Reinhardt, D. (2017). Supra-Regional Study Sites to Improve the Pediatric Oncologic Patient Care and Recruitment into Early-Phase Clinical Trials: A German Model. Pediatr. Blood Cancer, 64. S. S346 - 2. HOBOKEN: WILEY. ISSN 1545-5017

van Wezel, E., Decarolis, B., Stutterheim, J., Zappeij-Kannegieter, L., Hero, B., Berthold, F., Simon, T., Schumacher-Kuckelkorn, R., van Noesel, M., Fiocco, M., Caron, H., van der Schoot, C. E. and Tytgat, G. (2015). MINIMAL BONE MARROW DISEASE IS FREQUENTLY DETECTED IN LOCALIZED NEUROBLASTOMA PATIENTS. Pediatr. Blood Cancer, 62. S. S226 - 1. HOBOKEN: WILEY-BLACKWELL. ISSN 1545-5017

This list was generated on Sat Oct 23 03:26:22 2021 CEST.